Results 181 to 190 of about 93,713 (304)

Progression to type 1 diabetes across the autoimmunity and glycaemia continuum: Insights from real‐world paediatric and adult cohorts

open access: yesDiabetic Medicine, EarlyView.
Abstract Background Type 1 diabetes (T1D) follows a staged autoimmune natural history, yet most evidence describing progression derives from highly selected, genetically at‐risk cohorts. Methods Using the TriNetX Network, we identified eight cohorts of autoantibody‐positive individuals without prior T1D. Four cohorts had preserved glycaemia (HbA1c ≤5.6%
Matthew Anson   +7 more
wiley   +1 more source

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.
Hussain Salim   +9 more
wiley   +1 more source

Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang   +6 more
wiley   +1 more source

How to design desirable futures? Toward an integrated framework drawing on future‐forming and design science scholarship

open access: yesEuropean Management Review, EarlyView.
Abstract Many organizations and their stakeholders are facing major technological, societal, and geopolitical shifts, making it increasingly necessary to jointly shape desirable futures. This Perspective paper builds on Romme's research program that seeks to re‐introduce a problem‐solving (i.e., engineering) mindset in management research.
A. Georges L. Romme   +3 more
wiley   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn   +5 more
wiley   +1 more source

Endoscopic salvage of a complex post-endoscopic mucosal resection duodenal perforation. [PDF]

open access: yesEndoscopy
Paspatis GA   +6 more
europepmc   +1 more source

Subspecialty headache clinic visit reduced healthcare utilization in patients with migraine: Single institution retrospective cohort study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate whether care in a subspecialty headache center, compared with a general neurology clinic, was associated with lower 90‐day unplanned healthcare utilization (HCU) in patients with migraine and to identify patient‐level factors associated with higher unplanned HCU. Background Migraine is a common, disabling
Megan Trenz   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy